Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
Obesity · 2024-01 · 32 (1) · 50-58
DOI: 10.1002/oby.23922 ↗At a glance
Journal article in Obesity, published online on 2023-11-05. Written by Jean-Baptiste Bonnet and 13 co-authors. Institution: Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France. Major MEDLINE topics: Obesity, Morbid, Bariatric Surgery. Cited 35 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Objective
This retrospective cohort study aimed to assess the effectiveness of semaglutide 2.4 mg in patients with severe obesity (BMI ≥ 40 kg/m 2 ) who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss or experienced weight regain compared with patients without a history of BS with similar BMI.
Methods
The authors analyzed data from 129 patients with a BMI ≥ 40 kg/m 2 , including 39 with (BS+) and 90 without (BS−) a history of BS. The patients received semaglutide treatment for 24 weeks starting at 0.25 mg/wk and gradually increasing to reach a final dose of 2.4 mg/wk. The treatment outcomes were assessed based on the percentage of weight loss, changes in BMI, and waist circumference.
Results
Semaglutide treatment resulted in significant 9.1% weight loss in the BS+ group, with no significant difference in weight loss between the BS+ and BS− groups.
Conclusions
This study is the first, to the authors’ knowledge, to compare the effectiveness of semaglutide treatment in patients with versus those without a history of BS, providing valuable evidence of its efficacy. By focusing on individuals with severe obesity (BMI > 40 kg/m 2 and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France.
- Joint Research Unit (UMR) 1302, Desbrest Institute of Epidemiology and Public Health, University of Montpellier, INSERM, Montpellier, France.
- Institute of Functional Genomics, Joint Research Unit 5203, National Centre for Scientific Research (CNRS) U1191, INSERM, University of Montpellier, Montpellier, France.
- Department of Digestive Surgery, University Hospital of Montpellier, Montpellier, France.
- PhyMedExp, INSERM U1046, National Centre for Scientific Research (CNRS) Joint Research Unit (UMR) 9214, University of Montpellier, Montpellier, France.
ORCID profiles: Jean-Baptiste Bonnet, David Nocca, Ariane Sultan, Antoine Avignon
Cite
APA
Bonnet, J. B., Tournayre, S., Anitcheou, J., Faivre, M., Boegner, C., Jalek, A., Jullien, D., Attalin, V., Myzia, J., Marty, L., Kemba, Y., Nocca, D., Sultan, A., & Avignon, A. (2024). Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery. Obesity, 32(1), 50-58. https://doi.org/10.1002/oby.23922
Vancouver
Bonnet JB, Tournayre S, Anitcheou J, Faivre M, Boegner C, Jalek A, et al. Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery. Obesity. 2024;32(1):50-58. doi:10.1002/oby.23922
BibTeX
@article{Bonnet2024,
author = {Bonnet, Jean-Baptiste and Tournayre, Sarah and Anitcheou, Jean and Faivre, Marion and Boegner, Catherine and Jalek, Abdulkader and Jullien, Dominique and Attalin, Vincent and Myzia, Justine and Marty, Lucile and Kemba, Youadigue and Nocca, David and Sultan, Ariane and Avignon, Antoine},
title = {Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery},
journal = {Obesity},
year = {2024},
volume = {32},
number = {1},
pages = {50--58},
doi = {10.1002/oby.23922}
}
EUVIMED